Início › Câncer de Pâncreas › Carolina do Norte › Durham
Ensaios clínicos de Câncer de Pâncreas em Durham, NC
24 estudos para Câncer de Pâncreas estão buscando participantes em locais em Durham e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
The Vanguard Study: Testing a New Way to Screen for Cancer
RecrutandoVoluntários saudáveis bem-vindos
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
A Study of PHN-012 in Patients With Advanced Solid Tumors
RecrutandoFase 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
RecrutandoFase 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
RecrutandoEstudo observacional
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RecrutandoFase 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
- University of North Carolina Hospitals at Hillsborough, Hillsborough · a 13 mi de distância
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RecrutandoFase 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
RecrutandoFase 3
- Investigative Site US035, Chapel Hill · a 10 mi de distância
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecrutandoFase 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RecrutandoFase 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Recrutando
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
RecrutandoEstudo observacional
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
- University of North Carolina-Hillsborough Campus, Hillsborough · a 13 mi de distância
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
RecrutandoFase 2
- University of North Carolina, Chapel Hill · a 10 mi de distância
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecrutandoFase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · a 10 mi de distância
- University of North Carolina, Chapel Hill · a 10 mi de distância
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
RecrutandoFase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RecrutandoFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
RecrutandoFase 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecrutandoFase 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecrutandoFase 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
RecrutandoFase 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecrutandoFase 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
RecrutandoFase 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RecrutandoFase 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Chapel Hill · a 10 mi de distância
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RecrutandoFase 2
- University of North Carolina, Chapel Hill · a 10 mi de distância
Ensaios de Câncer de Pâncreas em outras cidades
- Houston, TX61 estudos
- New York City, NY60 estudos
- Boston, MA43 estudos
- Nashville, TN39 estudos
- Los Angeles, CA35 estudos
- St. Louis, MO33 estudos
- Arlington, VA33 estudos
- Baltimore, MD31 estudos
- San Antonio, TX31 estudos
- Philadelphia, PA26 estudos
- Tampa, FL26 estudos
- San Diego, CA24 estudos
Outros estudos em Durham
- Câncer de Mama64 estudos
- Câncer (todos os tipos)58 estudos
- Câncer de Pulmão de Não Pequenas Células39 estudos
- Mieloma Múltiplo37 estudos
- Leucemia Mieloide Aguda33 estudos
- Câncer Metastático33 estudos
- Câncer de Próstata32 estudos
- Câncer de Pulmão32 estudos
- Câncer Colorretal28 estudos
- Câncer de Ovário27 estudos
- Leucemia Linfocítica Crônica27 estudos
- Insuficiência Cardíaca26 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.